Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy (MASST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03712566|
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : February 27, 2019
|Condition or disease|
|Cancer Esophagus Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Anal Canal Squamous Cell Carcinoma Metastatic Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy|
|Actual Study Start Date :||November 6, 2018|
|Estimated Primary Completion Date :||October 2022|
|Estimated Study Completion Date :||October 2022|
Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
- Characterization of Genomic, epigenetic and Immune Profiling Features [ Time Frame: Through study completion, up to 4 years ]To comprehensively characterize genomic, epigenetic and immune profiling features and changes in longitudinal blood samples that are associated with systemic treatment of recurrent or metastatic squamous cell cancers of the head & neck, esophagus and anal canal.
- Establish a Clinically Annotated Biorepository [ Time Frame: Through study completion, up to 4 years ]To establish a clinically annotated biorepository of archived tumor and longitudinal blood samples, with serial radiomic evaluations in patients with recurrent/metastatic squamous cell cancers commencing on any new systemic treatments.
- Correlate Multi-Omic Results with Clinical Outcome [ Time Frame: Through study completion, up to 4 years ]To correlate genomic, othr-omic, radiomic and immune profiling results with clinical outcome - to identify potential predictive markers of response/resistance to systemic therapy.
- Compare HPV-Positive and HPV-Negative Cell Histologies [ Time Frame: Through study completion, up to 4 years ]To compare HPV-positive and HPV-negative squamous cell histology across three disease sites with multi-omic assessment.
- Investigate the Relationship Between Genomic Profiles and Radiomic Signatures [ Time Frame: Through study completion, up to 4 years ]To investigate whether any correlation or relation exists between tumor genomic profiles and radiomic imaging signatures.
- Enable Data-Sharing [ Time Frame: Though study completion, up to 4 years ]To enable data sharing with Queen's University Belfast as a collaborative initiative based on this project
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03712566
|Contact: Celeste Yu||416-946-4501 ext firstname.lastname@example.org|
|Contact: Samanta Del Rossi||416-946-4501 ext email@example.com|
|Princess Margaret Cancer Centre||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Celeste Yu 416-946-4501 ext 5281|
|Principal Investigator: Elena Elimova, MD|
|Principal Investigator:||Elena Elimova, MD||Princess Margaret Cancer Centre|